A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) with Pembrolizumab (KEYTRUDA) for Recurrent Glioblastoma or Gliosarcoma

Project: Research project

Description

A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) with Pembrolizumab (KEYTRUDA) for Recurrent Glioblastoma or Gliosarcoma
StatusActive
Effective start/end date5/31/185/31/23

Funding

  • DNATRIX, INC

Fingerprint

adenoviruses